CardioFocus HeartLight Post-Approval Study
Part of paid clinical trials in Tucson, Arizona.
- Sponsor
- CardioFocus
- Study ID
- NCT03168659
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- HeartLight — DEVICEHeartLight Endoscopic Ablation System
- Ablation — PROCEDUREPulmonary vein isolation ablation
Study Details
This is a post-approval study to evaluate the clinical outcomes in a cohort of participants treated during commercial use of the HeartLight System to confirm results of the previously conducted pivotal clinical study.
Key Dates
- Start date
- Jun 16, 2017
- Status verified
- Aug 2024
- Primary completion
- Oct 31, 2026
- Completion
- Oct 31, 2028
Study Design
- Enrollment
- 250 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Other: TreatmentPulmonary vein isolation ablation with HeartLight Endoscopic Ablation System
Primary Outcome Measure
The proportion of participants free from symptomatic atrial fibrillation (AF) or symptomatic atypical atrial flutter/atrial tachycardia (AFL/AT) lasting longer than 30 seconds post the 90 day blanking period [ Time Frame: Day 91 through 12 months ]
Central Contacts
- Study Director508-658-7253
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Arizona Sarver HeartCenter | Tucson | Arizona | 85724 | Mathew Hutchinson, MD (PRINCIPAL_INVESTIGATOR) |
| University of Illinois | Chicago | Illinois | 60612 | Erik Wissner, MD (PRINCIPAL_INVESTIGATOR) |
| Mount Sinai Hospital | New York | New York | 10029 | Betsy Ellsworth, MSN, ANP Srini Dukkipati, MD (PRINCIPAL_INVESTIGATOR) |
| University Of Virginia Health System | Charlottesville | Virginia | 22908 | J. Michael Mangrum, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Tucson, AZ
By condition
By specialty
Related Studies
- Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial FibrillationPHASE4 · Recruiting · University of Illinois at Chicago · Chicago, Illinois
- Anticoagulation in ICH Survivors for Stroke Prevention and RecoveryPHASE3 · Recruiting · Yale University · Birmingham, Alabama
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABGPHASE3 · Recruiting · Icahn School of Medicine at Mount Sinai · Little Rock, Arkansas
- Tracking Results of Ablations to Combat AF Registry Generation 2Recruiting · AtriCure, Inc. · Huntsville, Alabama